Methods:  We conducted a retrospective cohort study to identify

Methods:  We conducted a retrospective cohort study to identify

non-genetic risk factors for docetaxel–DILI among 647 metastasis breast cancer patients treated with docetaxel-containing regimens. Results:  Sixty-seven (10.36%) patients were diagnosed as docetaxel–DILI. By logistic regression analysis, premenopausal status (odds ratio [OR][95% confidence interval CI] = 2.24 [1.30–3.87]), past hepatitis B virus (HBV) infections (OR [95% CI] = 4.23 [1.57–11.42]), liver metastasis (OR [95% CI] = 3.70 [2.16–6.34]). The predominant occurrence of DILI was seen in groups with docetaxel combination regimens. (OR [95% CI] = 2.66 [1.59–4.55]). The potential increasing occurrence of docetaxel–DILI was associated with multiple risk factors in an exposure–response manner (P < 0.001), GSK-3 beta phosphorylation and patients with more than three risk factors would be exposed to a 36.61-fold risk of DILI (95% CI = 10.18–131.62). Further analysis by the risk score and area under the receiver–operator characteristic curve (AUC) showed that those four factors

contributed to an AUC of 0.7536 (95% CI = 0.70–0.81), with a predictive sensitivity of 74.63% and specificity of 65.17%. Conclusions:  Docetaxel–DILI with a relatively higher incidence should be addressed among metastatic breast cancer patients. Four predominant risk factors, Temozolomide manufacturer including premenopausal status, past HBV infection, liver metastasis, and docetaxel combination regimens, were potential predicators for DILI. “
“Aims:   Although bone marrow cells are reported to migrate to the liver under circumstances of severe liver 上海皓元 injury, the bone marrow cell type and the mechanisms in this process, remain to be clarified. We examined the involvement of hepatocyte growth factor (HGF) in this process and the cell type of migrated hematopoietic cells by HGF. Methods:  The CD34+ cells and colony forming

cells in the peripheral blood were examined in HGF transgenic, recombinant HGF-administered, and HGF-expressing adenovirus-administered mice. The cell type mobilized by HGF was examined by the percentages of donor cells in the peripheral blood of the recipient mice transplanted with Lin-c-kit+Sca-1+CD34+ cells and those with Lin-c-kit+Sca-1+CD34- cells. Expression of stem cell factor (SCF) was examined after the addition of HGF in MS-5 stromal cells. The numbers of the cells which were mobilized from bone marrow and recruited into liver by HGF were assessed using green fluorescence fluorescent (GFP)-chimera mice. Results:  Mobilized CD34+ cells and colony forming cells in the peripheral blood were increased by HGF treatment. The cells mobilized by HGF were mostly Lin-c-kit+Sca-1+CD34+ cells. Recruitment of bone marrow cells into liver was not suppressed in MMP-9-/- mice. Expression of SCF was induced by HGF in MS-5 stromal cells. However, expression of CXCR4, SDF-1, MMP-9 or VCAM-1 was not changed. The numbers of GFP-positive cells in liver 1 month after treatment by HGF was greater than that by G-CSF.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>